Global Brachytherapy Market Size, Share, and COVID-19 Impact Analysis, By Dosage Type (High-Dose Rate (HDR) Brachytherapy and Low-Dose Rate (LDR) Brachytherapy), By Product (Seeds, Applicators & Afterloaders, and Electronic Brachytherapy), By Application (Prostate Cancer, Gynaecological Cancer, Breast Cancer, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Brachytherapy Market Size Insights Forecasts to 2035

• The Global Brachytherapy Market Size Was Estimated at USD 1038.76 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 7.06% from 2025 to 2035
• The Worldwide Brachytherapy Market Size is Expected to Reach USD 2199.82 Million by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

Get more details on this report -

Request Free Sample PDF

The Global Brachytherapy Market Size was worth around USD 1038.76 million in 2024 and is predicted to grow to around USD 2199.82 million by 2035 with a compound annual growth rate (CAGR) of 7.06% from 2025 to 2035. The market growth is boosted by the rising cancer cases and its targeted, effective treatment benefits. Despite challenges in LMICs, ongoing innovation, training, and infrastructure development present strong growth potential for the market.

 

Market Overview 

The Brachytherapy Market Size refers to the radiation therapy as part of a specialist cancer treatment. It entails positioning a radioactive source close to or inside the tumor to accurately administer strong radiation while protecting neighboring healthy tissues. Because of its targeted approach and shortened treatment period, this treatment is frequently utilized for cancers such as skin, breast, prostate, and cervical cancers. The size of the market is mostly determined by cancer rates, technological developments, and public awareness of brachytherapy's advantages.

The market for brachytherapy is changing quickly as a result of the incorporation of cutting-edge technology like artificial intelligence and image-guided brachytherapy (IGBT). These developments are improving therapeutic outcomes by increasing therapy precision, safety, and customisation. Real-time treatment modifications and improved tumor visibility are made possible by seamless imaging integration. AI-driven planning systems are automatically identifying treatment irregularities and optimizing dose distribution. Healthcare providers are becoming more proficient in procedures due to specialized training systems. All things considered, these developments are transforming brachytherapy and changing the course of localized cancer treatment.

 

Report Coverage

This research report categorizes the brachytherapy market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the brachytherapy market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the brachytherapy market.

 

Driving Factors

Brachytherapy is becoming more widely used as a result of the expanding worldwide cancer burden and improved awareness of its therapeutic advantages. It is becoming the go-to option for accurate, successful treatment through support from oncology societies and technological developments.  Brachytherapy's incorporation into contemporary oncology care is supported by its capacity to administer tailored radiation with fewer adverse effects. However, there are major obstacles, particularly in LMICs, such as restricted access to cutting-edge equipment and a lack of qualified specialists. To close this gap, training and infrastructure expansion are essential. All things considered, the market has significant development potential with sustained innovation and assistance.

 

Restraining Factors

The market growth is hindered by the adoption of brachytherapy, which is severely hampered by its expensive initial setup costs and requirement for specialist infrastructure, especially in areas with limited resources. Its market penetration is further hampered by competing therapies like chemotherapy, surgery, and external beam radiation. Despite the clinical benefits of brachytherapy, these issues taken together delay its general implementation.

 

Market Segmentation

The brachytherapy market share is classified into dosage type, product, and application.

 

• The high-dose rate (HDR) brachytherapy segment dominated the market in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the dosage type, the brachytherapy market is classified into high-dose rate (HDR) brachytherapy and low-dose rate (LDR) brachytherapy. Among these, the high-dose rate (HDR) brachytherapy segment dominated the market in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The segmental growth can be attributed to an outpatient procedure. HDR brachytherapy can be utilized either as a stand-alone treatment or following tumor excision surgery.  Depending on the type of cancer being treated, the painless treatment may involve one or more sessions, Ziegler & Eckert. In the HDR brachytherapy market, some of the leading firms include BEBIG, Varian Medical Systems, and ELEKTA AB.

 

• The applicators & afterloaders segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the product, the brachytherapy market is divided into seeds, applicators & afterloaders, and electronic brachytherapy. Among these, the applicators & afterloaders segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. Applicators have a high degree of patient preference as they are less invasive and more effective than others. An apparatus known as an afterloader is used to move the radioactive sources to the treatment location. One radioactive source is briefly placed inside the tumor and then removed during HDR brachytherapy.

 

• The prostate cancer segment held the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the application, the brachytherapy market is classified into prostate cancer, gynaecological cancer, breast cancer, and others. Among these, the prostate cancer segment held the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The segmental growth can be attributed to the several benefits over alternative forms of therapy. These benefits include a shorter treatment duration, a quicker recovery, a lower risk of side effects because of the exact radiation dose delivery, an effective treatment for patients with prostate cancer recurrence, and the ability to safely increase the dose to the tumor while minimizing the dose to the surrounding organs, such as the rectum, bladder, and urethra.

 

Regional Segment Analysis of the Brachytherapy Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the brachytherapy market over the predicted timeframe.

Get more details on this report -

Request Free Sample PDF

North America is anticipated to hold the largest share of the brachytherapy market over the predicted timeframe. The regional growth can be attributed to the popularity of brachytherapy in North America because it has several benefits over conventional techniques, such as increased treatment effectiveness and safety. Regional expansion is additionally supported by a favorable reimbursement and regulatory environment. Furthermore, in order to preserve their market share and presence, businesses are increasingly investing in creating new goods and working with up-and-coming firms, as the investment landscape in the area has significantly changed.

 

Asia Pacific is expected to grow at a rapid CAGR in the brachytherapy market during the forecast period. The region's growth is being driven by the high prevalence of diseases and the target population's growing awareness. Furthermore, a lack of access to cutting-edge cancer treatments presents a number of opportunities for market participants. Furthermore, it is anticipated that the introduction of different brachytherapy systems in developing nations like India would have a favorable effect on the industry.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the brachytherapy market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Varian Medical Systems, Inc.
• Theragenics Corporation
• Becton
• CIVCO Medical Solutions
• Dickinson & Company
• iCAD, Inc.
• Elekta AB
• Eckert & Ziegler BEBIG
• Isoray Medical, Inc.
• IBA
• Isoray, Inc
• P-Cure Ltd 
• Panacea Medical Technologies Pvt Ltd
• RaySearch Laboratories AB
• Others.

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

 

Recent Development

• In March 2025, BEBIG Medical introduced its innovative SagiNova brachytherapy system at Father Muller Medical College Hospital (FMMCH), coinciding with the opening of a new healthcare wing and the 184th birthday of the hospital's founder. This strategic deployment improves cancer care capabilities at FMMCH by allowing for accurate, high-dose radiation therapy at a lower cost, making cutting-edge treatment more accessible to marginalized people.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the brachytherapy market based on the below-mentioned segments: 

 

Global Brachytherapy Market, By Dosage Type

• High-Dose Rate (HDR) Brachytherapy
• Low-Dose Rate (LDR) Brachytherapy

 

Global Brachytherapy Market, By Product

• Seeds
• Applicators & Afterloaders
• Electronic Brachytherapy

 

Global Brachytherapy Market, By Application

• Prostate Cancer
• Gynaecological Cancer
• Breast Cancer
• Others

 

Global Brachytherapy Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa